249 related articles for article (PubMed ID: 30368218)
1. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
3. Aptima Human Papillomavirus E6/E7 mRNA Test Results Strongly Associated With Risk for High-Grade Cervical Lesions in Follow-Up Biopsies.
Ge Y; Christensen P; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR
J Low Genit Tract Dis; 2018 Jul; 22(3):195-200. PubMed ID: 29543688
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
5. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
7. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
8. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
[TBL] [Abstract][Full Text] [Related]
9. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
10. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study.
Castle PE; Cuzick J; Stoler MH; Wright TC; Reid JL; Dockter J; Giachetti C; Getman D
Am J Clin Pathol; 2015 Feb; 143(2):160-7. PubMed ID: 25596241
[TBL] [Abstract][Full Text] [Related]
11. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
12. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
14. Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay.
Borgfeldt C; Forslund O
J Virol Methods; 2019 Aug; 270():18-20. PubMed ID: 31002831
[TBL] [Abstract][Full Text] [Related]
15. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
16. Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
Wang J; Dong J; Zhou Y; Wang K; Pan M; Deng Z; Wang P; Du Y; Lu W
Gynecol Oncol; 2022 Mar; 164(3):607-614. PubMed ID: 34996586
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Clinical Performance of Aptima HPV Assay and the Cobas 4800 Platform in Women with Normal Cytology and Positive High-Risk HPV.
Kir G; Dokmeci Guney D; Seneldir H
Acta Cytol; 2023; 67(4):395-402. PubMed ID: 36977394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
